{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T22:15:46Z","timestamp":1792880146236,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jdcjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.jdiacomp.2016.04.020","type":"journal-article","created":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:35:47Z","timestamp":1462062947000},"page":"1192-1200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetes\u2014Network meta-analysis of randomized trials"],"prefix":"10.1016","volume":"30","author":[{"given":"Luciana R.","family":"Remonti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2172-0221","authenticated-orcid":false,"given":"Sofia","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane B.","family":"Leit\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline K.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas P.","family":"Klassman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicky J.","family":"Welton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.E.","family":"Ades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge L.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0260","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","article-title":"Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study","volume":"321","author":"Adler","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0115","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/01.HYP.0000143851.23721.26","article-title":"Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study","volume":"44","author":"Bakris","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0015","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1751-7176.2008.00012.x","article-title":"ASH position paper: Treatment of hypertension in patients with diabetes-an update","volume":"10","author":"Bakris","year":"2008","journal-title":"Journal of Clinical Hypertension (Greenwich, Conn.)"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0120","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0125","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group. Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy","volume":"138","author":"Berl","year":"2003","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0130","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0045","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: Combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0135","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1001\/jama.1996.03540230036032","article-title":"Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group","volume":"276","author":"Curb","year":"1996","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jdiacomp.2016.04.020_bb0040","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"A evidence synthesis for decision making 2: A generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Medical Decision Making"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0100","author":"Dias"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0085","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Statistics in Medicine"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0095","author":"Dias"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0140","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199803053381003","article-title":"The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension","volume":"3389","author":"Estacio","year":"1998","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0010","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0140-6736(12)60987-8","article-title":"Diabetes and hypertension: The bad companions","volume":"380","author":"Ferrannini","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0145","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0895-7061(02)03017-0","article-title":"Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients","volume":"15","author":"Fogari","year":"2002","journal-title":"American Journal of Hypertension"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1741-7015-10-33","article-title":"Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: Systematic review and multiple treatments meta-analysis","volume":"10","author":"Fretheim","year":"2012","journal-title":"BMC Medicine"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0075","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence--publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0070","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","article-title":"GRADE guidelines 11-making an overall rating of confidence in effect estimates for a single outcome and for all outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0270","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0150","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","article-title":"Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study","volume":"356","author":"Hansson","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0090","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0155","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: A multicentre, randomised, placebo-controlled study","volume":"54","author":"Imai","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0160","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0065","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0165","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1097\/00004872-200018110-00020","article-title":"Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: Results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group","volume":"18","author":"Lindholm","year":"2000","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0170","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol","volume":"359","author":"Lindholm","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0105","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jval.2011.05.042","article-title":"Consistency between direct and indirect trial evidence: Is direct evidence always more reliable?","volume":"14","author":"Madan","year":"2011","journal-title":"Value in Health"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0175","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/01.HYP.0000057420.27692.AD","article-title":"Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT)","volume":"41","author":"Mancia","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0180","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/01.hjh.0000133733.32125.09","article-title":"Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR study","volume":"22","author":"Marre","year":"2004","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0185","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/HYPERTENSIONAHA.111.184226","article-title":"Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART study","volume":"59","author":"Muramatsu","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0190","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/hr.2010.38","article-title":"Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial","volume":"33","author":"Nakao","year":"2010","journal-title":"Hypertension Research"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0195","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.2337\/diab.46.7.1182","article-title":"Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy","volume":"46","author":"Nielsen","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0200","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.2337\/diacare.24.12.2091","article-title":"Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic\/beta-blocker-based treatment regimen: A subanalysis of the Captopril Prevention Project","volume":"24","author":"Niskanen","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0275","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.amjmed.2011.12.010","article-title":"Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients","volume":"125","author":"Ogawa","year":"2012","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0205","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1097\/HJH.0b013e328310e0d9","article-title":"The Anglo-Scandinavian Cardiac Outcomes Trial: Blood pressure-lowering limb: Effects in patients with type II diabetes","volume":"26","author":"Ostergren","year":"2008","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0210","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"The New England Journal of Medicine"},{"issue":"4 Suppl. 2","key":"10.1016\/j.jdiacomp.2016.04.020_bb0215","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1681\/ASN.2005121324","article-title":"Prevention and treatment of diabetic renal disease in type 2 diabetes: The BENEDICT study","volume":"17","author":"Remuzzi","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0060","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/ije\/31.1.150","article-title":"Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed","volume":"31","author":"Robinson","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0255","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0220","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/HJH.0b013e32834069bd","article-title":"Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: The BENEDICT-B randomized trial","volume":"29","author":"Ruggenenti","year":"2011","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0225","first-page":"768","article-title":"Syst-Eur Trial: Benefits of nitrendipine in the type 2 diabetic hypertensive patients","volume":"96","author":"Safar","year":"2003","journal-title":"Archives des Maladies du Coeur et des Vaisseaux"},{"issue":"Suppl. 1","key":"10.1016\/j.jdiacomp.2016.04.020_bb0025","first-page":"S14","article-title":"Standards of medical care in diabetes\u20142014","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0230","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/diacare.21.4.597","article-title":"Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM","volume":"21","author":"Tatti","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0235","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199903043400902","article-title":"Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators","volume":"340","author":"Tuomilehto","year":"1999","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0035","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archinte.165.12.1410","article-title":"Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials","volume":"165","author":"Turnbull","year":"2005","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0020","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0110","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","article-title":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0005","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7326\/0003-4819-138-7-200304010-00018","article-title":"Treatment of hypertension in type 2 diabetes mellitus: Blood pressure goals, choice of agents, and setting priorities in diabetes care","volume":"138","author":"Vijan","year":"2003","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0240","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2010.02.046","article-title":"Cardiovascular events during differing hypertension therapies in patients with diabetes","volume":"56","author":"Weber","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0080","series-title":"Evidence synthesis for decision making in healthcare","author":"Welton","year":"2012"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0245","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archinte.165.12.1401","article-title":"Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Whelton","year":"2005","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1016\/j.jdiacomp.2016.04.020_bb0030","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008161","article-title":"First-line drugs for hypertension","volume":"8","author":"Wright","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0055","doi-asserted-by":"crossref","first-page":"f6008","DOI":"10.1136\/bmj.f6008","article-title":"Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: Systematic review and bayesian network meta-analysis","volume":"347","author":"Wu","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2016.04.020_bb0250","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1291\/hypres.27.449","volume":"27","author":"Yui","year":"2004","journal-title":"Hypertension Research"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716301192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716301192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T02:18:57Z","timestamp":1567822737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872716301192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S1056872716301192"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.04.020","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetes\u2014Network meta-analysis of randomized trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}